Sangivamycin

Sangivamycin is a natural product originally isolated from Streptomyces rimosus, which is a nucleoside analogue. It acts as an inhibitor of protein kinase C. It has antibiotic, antiviral and anti-cancer properties and has been investigated for various medical applications, though never approved for clinical use itself. However, a number of related derivatives continue to be researched.^{[1][2][3][4][5][6][7]}

CAS Number

• 18417-89-5

PubChem CID

• 14978

ChemSpider

• 14261

UNII

• L8YQ8Z3T9T

Quick facts Identifiers, CAS Number ...

Sangivamycin

Identifiers
IUPAC name 4-amino-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrrolo[2,3-d]pyrimidine-5-carboxamide
CAS Number	18417-89-5
PubChem CID	14978
ChemSpider	14261
UNII	L8YQ8Z3T9T
ChEBI	CHEBI:85997
ChEMBL	ChEMBL101892
ECHA InfoCard	100.162.068
Chemical and physical data
Formula	C12H15N5O5
Molar mass	309.282 g·mol−1
3D model (JSmol)	Interactive image
SMILES C1=C(C2=C(N=CN=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O)N)C(=O)N
InChI InChI=1S/C12H15N5O5/c13-9-6-4(10(14)21)1-17(11(6)16-3-15-9)12-8(20)7(19)5(2-18)22-12/h1,3,5,7-8,12,18-20H,2H2,(H2,14,21)(H2,13,15,16)/t5-,7-,8-,12-/m1/s1 Key:OBZJZDHRXBKKTJ-JTFADIMSSA-N

Close

Oyagen, a biotechnology company, has been developing sangivamycin or OYA1, which showed efficacy against Ebola infections,^[8] as a broad spectrum antiviral for COVID-19.^[9][10] Tonix Pharmaceuticals licensed OYA1 from Oyagen in April 2021 to develop it for the treatment of COVID-19 and it is now called TNX-3500.^[11][12][13] In July 2022, Tonix announced that it was terminating development of TNX-3500, an antiviral inhibitor of SARS-CoV-2, and the associated licence agreement with OyaGen, Inc. was expected to be terminated, effective September 20, 2022.^[14]